Medical therapy of epilepsy

Expert Opinion on Therapeutic Patents

Volumn 17, Issue 8, 2007, Pages 955-964

  Arain, Amir M ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Antiepileptic medications; Epilepsy; Generalized epilepsy; Partial epilepsy; Seizures

Indexed keywords

ANTICONVULSIVE AGENT; CALCIUM CHANNEL BLOCKING AGENT; CARBAMAZEPINE; CENTRAL DEPRESSANT AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; DIGOXIN; ESTROGEN DERIVATIVE; ETIRACETAM; FELBAMATE; FELBATAL; GABAPENTIN; LAMOTRIGINE; ORAL CONTRACEPTIVE AGENT; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; PLACEBO; PREGABALIN; TIAGABINE; TOPIRAMATE; VALPROATE SEMISODIUM; VALPROIC ACID; ZONISAMIDE;

ACIDOSIS; ADD ON THERAPY; ADJUVANT THERAPY; AGGRESSION; AGITATION; ANOREXIA; ANTICONVULSANT ACTIVITY; ANXIETY DISORDER; APLASTIC ANEMIA; ASTHENIA; ATAXIA; BLURRED VISION; BRAIN DISEASE; CLINICAL TRIAL; COGNITIVE DEFECT; DEPRESSION; DIABETIC NEUROPATHY; DIARRHEA; DIPLOPIA; DISEASE ASSOCIATION; DIZZINESS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG ELIMINATION; DRUG ERUPTION; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG METABOLISM; DRUG POTENCY; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG UPTAKE; DRUG WITHDRAWAL; EPILEPSY; FATIGUE; GASTROINTESTINAL SYMPTOM; GRAND MAL SEIZURE; HUMAN; HYPERAMMONEMIA; HYPERTHERMIA; HYPONATREMIA; INSOMNIA; IRRITABILITY; KETOGENIC DIET; LENNOX GASTAUT SYNDROME; LEUKOPENIA; LIVER FAILURE; LIVER TOXICITY; LOW DRUG DOSE; MAINTENANCE THERAPY; MONOTHERAPY; MOOD DISORDER; MYOCLONUS SEIZURE; NAUSEA; NEPHROLITHIASIS; NERVOUSNESS; PATENT; POSTHERPETIC NEURALGIA; PSYCHOSIS; REVIEW; SIDE EFFECT; SOMNOLENCE; TONIC CLONIC SEIZURE; VISUAL HALLUCINATION; WEIGHT GAIN; WEIGHT REDUCTION;

EID: 34548312127     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543776.17.8.955     Document Type: Review

References (53)

1. HAUSER WA, ANNEGERS JF, ROCCA WA: Descriptive epidemiology of epilepsy: contributions of population-based studies from Rochester, Minnesota. Mayo. Clin. Proc. (1996) 71(6):576-586.
2. HAUSER WA, HESDORFFER DC: Epilepsy: Frequency, Causes and Consequences. (Ed.), Demos Press, New York, (1991):21-28.
3. ANNEGERS JF: The Epidemiology of Epilepsy. In The Treatment of Epilepsy: Principles and Practice. E W (Ed.), Lippincott Williams and Wilkins, Philadelphia, PA (2001):131-138.
4. DAM M: Goals of therapy. In: Epilepsy: A Comprehensive Textbook. Jr EJ et al. (Eds), Lippincott-Raven, Philadelphia, Pa (1997):1103-1105.
5. KWAN P, BRODIE MJ: Early identification of refractory epilepsy. N. Engl. J. Med. (2000) 342(5):314-319.
6. MARSON AG, KADIR ZA, CHADWICK DW: New antiepileptic drugs: a systematic review of their efficacy and tolerability. BMJ (1996) 313(7066):1169-1174.
7. GAMBLE CL, WILLIAMSON PR, MARSON AG: Lamotrigine versus carbamazepine monotherapy for epilepsy. Cochrane Database Syst. Rev. (2006) (1): CD001031.
8. PELLOCK JM, BRODIE MJ: Felbamate: 1997 update. Epilepsia (1997) 38(12):1261-1264.
9. WHITE HS: Comparative anticonvulsant and mechanistic profile of the established and newer antiepileptic drugs. Epilepsia (1999) 40(Suppl. 5):S2-S10.
10. GLUE P, BANFIELD CR, PERHACH JL et al.: Pharmacokinetic interactions with felbamate. Clin. Pharmacokinet. (1997) 33(3):214-224.
11. PELLOCK JM: Felbamate. Epilepsia (1999) 40(Suppl. 5):S57-S62.
12. GEE NS, BROWN JP, DISSANAYAKE VU et al.: The novel anticonvulsant drug, gabapentin (Neurontin), binds to the α2δ subunit of a calcium channel. J. Biol. Chem. (1996) 271(10):5768-5776.
13. CHADWICK D, LEIDERMAN DB, SAUERMANN W, ALEXANDER J, GAROFALO E: Gabapentin in generalized seizures. Epileosy Res. (1996) 25(3):191-197.
14. SHORVON S, STEFAN H: Overview of the safety of newer antiepileptic drugs. Epilepsia (1997) 38(Suppl. 1):S45-S51.
15. GIDAL BE, DECERCE J, BOCKBRADER HN et al.: Gabapentin bioavailability: effect of dose and firquency of administration in adult patients with epilepsy. Epilepsy Res. (1998) 31(2):91-99.
16. BRODIE MJ: Lamotrigine - an update. Can. J. Neurol. Sci. (1996) 23(4):S6-S9.
17. FITTON A, GOA KL: Lamotrigine. An update of its pharmacology and therapeutic use in epilepsy. Drugs (1995) 50(4):691-713.
18. BRODIE MJ, RICHENS A, YUEN AW: Double-blind comparison of lamotrigine and carbamazepinc in newly diagnosed epilepsy. UK Lamotrigine/ Carbamazepine Monotherapy Trial Group. Lancet (1995) 345(8948):476-479.
19. BITON V, SACKELLARES JC, VUONG A et al.: Double-blind, placebo-controlled study of lamotrigine in primary generalized tonic-clonic seizures. Neurology (2005) 65(11):1737-1743.
20. GUERRINI R, DRAVET C, GENTON P et al.: Lamotrigine and seizure aggravation in severe myoclonic epilepsy. Epilepsia (1998) 39(5):508-512.
21. BENBADIS SR: Practical management issues for idiopathic generalized epilepsies. Epilepsia (2005) 46(Suppl. 9):125-132.
22. SIDHU J, JOB S, SINGH S, PHILIPSON R: The pharmacokinetic and pharmacodynamic consequences of the co-administration of lamotrigine and a combined oral contraceptive in healthy female subjects. Br. J. Clin. Pharmacol. (2006) 61(2):191-199.
23. PERUCCA E: A pharmacological and clinical review on topiramate, a new antiepileptic drug. Pharmacol. Res. (1997) 35(4):241-256.
24. SOUSA PDA S, ARAUJO FILHO GM, GARZON E, SAKAMOTO AC, YACUBIAN EM: Topiramate for the treatment of juvenile myoclonic epilepsy. Arq. Neuropsiquiatr. (2005) 63(3B):733-737.
25. LANGTRY HD, GILLIS JC, DAVIS R: Topiramate. A review of its pharmacodynamic and pharmacokinetic properties and clinical efficacy in the management of epilepsy. Drugs (1997) 54(5):752-773.
26. DICHTER MA, BRODIE MJ: New antiepileptic drugs. N. Engl. J. Med. (1996) 334(24):1583-1590.
27. ECKARDT KM, STEINHOFF BJ: Non-convulsive status epilepticus in two patients receiving tiagabine treatment. Epilepsia (1998) 39(6):671-674.
28. ETTINGER AB, BERNAL OG, ANDRIOLA MR et al.: Two cases of non-convulsive status epilepticus in association with tiagabine therapy. (0013-9580 (Print)).
29. KLITGAARD H, MATAGNE A, GOBERT J, WULFERT E: Evidence for a unique profile of levetiracetam in rodent models of seizures and epilepsy. Eur. J. Pharmacol. (1998) 353(2-3):191-206.
30. LAMBENG N, GILLARD M, VERTONGEN P, FUKS B, CHATELAIN P: Characterization of [(3)H]ucb 30889 binding to synaptic vesicle protein 2A in the rat spinal cord. Eur. J. Pharmacol. (2005) 520(1-3):70-76.
31. CEREGHINO JJ, BITON V, ABOU-KHALIL B et al.: Levetiracetam for partial seizures: results of a double-blind, randomized clinical trial. Neurology (2000) 55(2):236-242.
32. ABOU-KHALIL B, LAZENBY B: Long-term experience with levetiracetam. Epileptic Disord. (2003) 5(Suppl. 1):S33-S37.
33. KALIS MM, HUFF NA: Oxcarbazepine, an antiepileptic agent. Clin. Ther. (2001) 23(5):680-700; discussion 645.
34. SCHMIDT D, ELGER CE: What is the evidence that oxcarbazepine and carbamazepine are distinctly different antiepileptic drugs? Epilepsy Behav (2004) 5(5):627-635.
35. FATTORE C, CIPOLLA G, GATTI G et al.: Induction of ethinylestradiol and levonorgestrel metabolism by oxcarbazepine in healthy women. Epilepsia (1999) 40(6):783-787.
36. GELISSE P, GENTON P, KUATE C, PESENTI A, BALDY-MOULINIER M, CRESPEL A: Worsening of seizures by oxcarbazepine in juvenile idiopathic generalized epilepsies. (0013-9580 (Print)).
37. ASCONAPE JJ: Some common issues in the use of antiepileptic drugs. Semin. Neurol. (2002) 22(1):27-39.
38. PETERS DH, SORKIN EM: Zonisamide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in epilepsy. Drugs (1993) 45(5):760-787.
39. KOTHARE SV, VALENCIA I, KHURANA DS et al.: Efficacy and tolerability of zonisamide in juvenile myoclonic epilepsy. Epileptic Disord (2004) 6(4):267-270.
40. ARROYO S, ANHUT H, KUGLER AR et al.: Pregabalin add-on treatment: a randomized, double-blind, placebo-controlled, dose-response study in adults with partial seizures. Epilepsia (2004) 45(1):20-27.
41. FRENCH JA, KUGLER AR, ROBBINS JL, KNAPP LE, GAROFALO EA: Dose-response trial of pregabalin adjunctive therapy in patients with partial seizures. Neurology (2003) 60(10):1631-1637.
42. BEYDOUN A, UTHMAN BM, KUGLER AR et al.: Safety and efficacy of two pregabalin regimens for add-on treatment of partial epilepsy. Neurology (2005) 64(3):475-480.
43. HAMANDI K, SANDER JW: Pregabatin: a new antiepileptic drug for refractory epilepsy. Seizure (2006) 15(2):73-78.
44. BRODIE MJ: Pregabalin as adjunctive therapy for partial seizures. Epilepsia (2004) 45 (Suppl. 6):19-27.
45. MARSON AG, AL-KHARUSI AM, ALWAIDH M et al.: The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial. (1474-547X (Electronic))
46. MARSON AG, AL-KHARUSI AM, ALWAIDH M et al.: The SANAD study of effectiveness of valproate, lamotrigine, or topirarnate for generalised and unclassifiable epilepsy: an unblinded randomised controlled trial. (1474-5417X (Electronic))
47. BEGHI E, ANNEGERS JF: Pregnancy registries in epilepsy. Epilepsia (2001) 42(11):1422-1425.
48. SABERS A, DAM M, A-ROGVI-HANSEN B et al.: Epilepsy and pregnancy: lamotrigine as main drug used. (0001-6314 (Print))
49. TEN BERG K, SAMREN EB, SAMREN EB, VAN OPPEN AC, ENGELSMAN M: Levetiracetam use and pregnancy outcome Epilepsy and pregnancy: lamotrigine as main drug used influence of major antiepileptic drugs on attention, reaction time, and speed of information processing: results from a randomized, double-blind, placebo-controlled withdrawal study of seizure-free epilepsy patients receiving monotherapy Side Fffect Profiles and Behavioral Consequences of Antiepileptic Medications New anticonvulsants-new adverse effects. (0890-6238 (Print)).
50. LB H, DF W, EJ B et al.: Increased risk for non-syndromic cleft palate among infants exposed to lamotrigine during pregnancy (abstract). Birth Defects Research Part A: Clinical and Molecular Teratology (2006).
51. LEE S, SZIKLAS V, ANDERMANN F et al.: The effects of adjunctive topiramate on cognitive function in patients with epilepsy. Epilepsia (2003) 44(3):339-347.
52. PACK AM, MORRELL MJ, MARCUS R et al.: Bone mass and turnover in women with epilepsy on antiepileptic drug monotherapy. Ann. Neurol. (2005) 57(2):252-257.
53. STEPHEN LJ, MCLELLAN AR, HARRISON JH et al.: Bone density and antiepileptic drugs: a case-controlled study. Seizure (1999) 8(6):339-342.